research centers


Search results: Found 2

Listing 1 - 2 of 2
Sort by

Article
Effect of the Biological Drug Etanercept on Tumor necrosis factor-α Levels in Psoriatic Patients

Authors: Basman Medhat Fadheel --- Ban Noori Al-Qadhi --- Rasha Hussain Kuba
Journal: Iraqi Journal of Science المجلة العراقية للعلوم ISSN: 00672904/23121637 Year: 2018 Volume: 59 Issue: 2C Pages: 998-1005
Publisher: Baghdad University جامعة بغداد

Loading...
Loading...
Abstract

Psoriasis is a common, chronic, immune mediated disorder.The disease is arising as a result of dysregulated interactions of the innate and adaptive immune system in the context of skin epithelium and connective tissue. The biological drug Etanercept(ETN) approved for use in treated psoriasis. ETN is tumor necrosis factor- α (TNF-α) inhibitor. In this study, 48 psoriatic patients were taken before and after treatment who attended to the Dermatology and Venereology Department in Baghdad Teaching Hospital during the period from December 2016 to September 2017and 50 samples were used as healthy control group. The results showed that most psoriatic patients 52.08 % were within the second and third decades 20-35 year, and the majority of psoriatic patients were males 62.5% and the ratio of male to female is 1.67:1. Moreover, the results demonstrated that the males were more expected psoriasis compare with females. Blood samples were collected and TNF- α was estimated in sera of all subjects by using Enzyme Linked Immunosorbent Assay (ELISA). The TNF- α mean levels in psoriatic patients before treatment was 189.5±26.0 ng/ml, and after treatment was 223.6±41.1 ng/ml compar with the healthy control group 93.5±2.4 ng/ml. The results showed significant differences between the studied groups


Article
Effects of Methotrexate and Etanercept on C-Reactive Protein and Anti-Cyclic Citrullinated Peptide Antibodies level In Rheumatoid Arthritis Patients
آثار الميثوتريكسيت وetanercept وعلى بروتين سي التفاعلي ومستوى مكافحة دوري Citrullinated الببتيد الأجسام المضادة في التهاب المفاصل الروماتويدي المرضى

Authors: Khawla H. Zhair خولة زهير --- Rasha Hussain Kuba رشا حسين --- Yasser abdulhussain Jafar ياسر عبد الحسين
Journal: Al-Kufa University Journal for Biology مجلة جامعة الكوفة لعلوم الحياة ISSN: 20738854 23116544 Year: 2016 Issue: Special Second International Scientific Conference for the Life Sciences Pages: 120-124
Publisher: University of Kufa جامعة الكوفة

Loading...
Loading...
Abstract

Rheumatoid Arthritis (RA) is an autoimmune disease. The treatment of this disease by taking Etnercept and Methotrexate (MTX) drugs. This study was conducted to detect C-Reactive Protein (C-RP) and Anti- Citrullinated Peptide Antibodies (Anti-CCP Abs) level among 126 rheumatoid arthritis (RA) patients treated with Etanercept (ETN) and methotrexate (MTX), 94 RA patients treated with MTX, 80 RA patients without treatment and 100 samples as healthy control. Blood samples were collected and the presence of C-RP antibodies was determined by using Latex agglutination test (LAT). Anti-CCP Abs was also estimated in serum of all subjects by using Enzyme linked immunosorbent assay (ELISA) method too. The seroprevalence of C-RP in RA+ETN+MTX was 57(45.24%), in RA+MTX was 62(65.96%), in untreated RA patients was 53(66.25%) while, it was 5(5%)in healthy group. The mean levels of Anti-CCP Abs in RA+ETN+MTX patients were (18.53± 1.70 pg/ml), in RA+MTX patients was (47.61± 6.24 pg/ml), and in untreated RA patients was (167.98 ± 8.67 pg/ml)while, they were (10.3 pg/ml ± 0.87) in healthy group. The results showed significant difference (P<0.05) for both C-RP prevalence and Anti-CCP Abs serum levels was found between studied subjects.

التهاب المفاصل الروماتويدي (RA) هو أحد أمراض المناعة الذاتية. علاج هذا المرض عن طريق تعاطي المخدرات Etnercept والميثوتريكسيت (MTX). وقد أجريت هذه الدراسة للكشف عن بروتين سي التفاعلي (سي آر بي) ومكافحة Citrullinated الببتيد الأجسام المضادة (مضاد للCCP عبس) مستوى بين 126 التهاب المفاصل الروماتيزمي (RA) المرضى الذين عولجوا مع etanercept و(ETN) والميثوتريكسيت (MTX)، 94 RA المرضى الذين عولجوا مع MTX، 80 مرضى التهاب المفاصل الروماتويدي من دون علاج، و 100 عينات السيطرة كما صحية. تم جمع عينات الدم وتم تحديد وجود أجسام مضادة C-RP باستخدام اختبار تراص اللاتكس (LAT). وقدرت مكافحة CCP عبس أيضا في مصل الدم من جميع المواد الدراسية باستخدام انزيم مرتبط طريقة الفحص المناعي (ELISA) أيضا. وكان الانتشار المصلي من C-RP في الاتحاد الإقليمي + ETN + MTX 57 (45.24٪)، في RA + MTX كان 62 (65.96٪)، في و53 (66.25٪)، في حين، كان مرضى التهاب المفاصل الروماتويدي غير المعالجة 5 (5٪) في مجموعة صحية. وكانت المستويات الوسيطة لمكافحة CCP عبس في الاتحاد الإقليمي + ETN + MTX المرضى (18.53 ± 1.70 جزء من الغرام / مل)، في RA + المرضى MTX كان (47.61 ± 6.24 جزء من الغرام / مل)، وفي مرضى التهاب المفاصل الروماتويدي غير المعالجة كان (167.98 ± 8.67 جزء من الغرام / مل) بينما كانت (10.3 غ / مل ± 0.87) في مجموعة صحية. أظهرت النتائج فروق معنوية (P <0.05) لكل من انتشار C-RP ومكافحة CCP عبس مستويات المصل تم العثور بين المواضيع التي شملتها الدراسة.

Listing 1 - 2 of 2
Sort by
Narrow your search

Resource type

article (2)


Language

English (2)


Year
From To Submit

2018 (1)

2016 (1)